Carlo Incerti MD
Operating Partner
Numab Therapeutics is a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology and oncology.
The company is developing multispecific antibody-based immunotherapies for inflammation, cancer and diseases with high unmet need.
Reproducible plug-and-play therapeutic design process using proprietary platforms A-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery barriers in multispecific biologics and build a pipeline of new and important medicines aimed to maximize patient benefits. Numab’s diverse research pipeline spans multiple therapeutic areas and creates the opportunity for the next generation of first-in-class and best-in-class medicines.
Industry
Biotech
Status
Current
Location
Switzerland
With Forbion's backing, we built a diversified pipeline of multi-specific therapeutics based on a differentiated platform. We mitigated risks through strategic partnerships in Asia and achieved a significant milestone by selling a therapy for atopic dermatitis to Johnson & Johnson for USD 1.25 billion in an all-cash upfront deal, while retaining our platform and remaining pipeline. Forbion's unwavering support and strategic guidance were instrumental in our success. They recognized Numab's potential early on, providing strong support on our board and remaining loyal and committed during challenging times.David Urech
Director, Chair R&D Committee
12
Pharma partnerships
Forbion team
Nanna Lüneborg PhD, MBA
General Partner